clinical trial · NCT07370207
Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region
AusperBio Therapeutics Inc.·phase2·recruiting·n = 84
Hepatitis B, ChronicAHB-137
brief summary
This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with NAs.
started
Mar 6, 2026
primary completion
Dec 31, 2028
completion
Dec 31, 2028
last updated
Apr 13, 2026
official title
A Phase 2 Multi-center, Randomized, Open-label Study to Assess the Efficacy and Safety of AHB-137 in Nucleos(t)Ide Analogue-treated Participants With HBeAg Negative Chronic Hepatitis B in the Asia Pacific Region
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol